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ABSTRACT 
 
Rosiglitazone withdrawal from the market has led to a renewed interest 
in the Peroxisome Proliferator Activated Receptor γ (PPARγ) as target 
for hypoglycaemic therapy – this time, via partial agonism. This may  
be achieved by using selective PPARγ modulators such as S-26948. A  
receptor-based drug design approach was adopted in this study, using 
the bound conformation of rosiglitazone within the PPARγ ligand 
binding pocket to identify S-26948 conformers, and consequently 
generate high affin ity novel molecules . S-26948 conformer 17 was 
chosen, which exhibited an alternative binding modality with respect 
to rosiglitazone. Ligand binding pocket mapping of this orientation 
identified a larger pocket with respect to that delineated by  the bound 
coordinates of rosiglitazone, and an additional theoretical novel pocket 
within  PPARγ. Therefore, currently  used PPARγ ligands  may not 
occupy the entire breadth of the ligand binding pocket, warranting 
further investigation from a receptor modality point of view. Key  
words: T2DM, PPAR, SPPARγMs, Thiazo lidinediones, S-26948. 
 
Introduction: 
 Peroxisome Proliferator Activated Receptors 
(PPARs) represent a family of nuclear receptors (NRs) which 
are at the basis of various metabolic processes within the 
body – including glycaemic control1. Three subtypes of the 
PPAR receptor – the α, the γ, and the β/δ have been 
described2,3,4, of which, the major target for glycaemic 
control in Type II Diabetes Mellitus (T2DM) is the γ subtype, 
as exemplified by the thiazolidinediones (TZDs)3,5,6. The 
2010 withdrawal of rosiglitazone7, a TZD, from the market, 
has left a lacuna in contemporary hypoglycaemic therapy – in 
turn spurring renewed rational design efforts at PPARγ as a 
design target.   
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 There is evidence3 in the literature that different 
ligands bring about their action on the PPARγ receptor 
according to their structure – via the degree of Helix 12 
(H12) stabilisation. Full agonists, such as the recently 
withdrawn rosiglitazone7, stabilise H12 enough to recruit  
coactivators to a high extent, while partial agonists or 
selective PPARγ modulators (SPPARγMs), bring about  
improper H12 stabilisation – hence leading to a lesser 
recruitment of coactivators and/or lesser dissociation of 
corepressors.3 This is the theoretical basis behind newer 
PPARγ-directed approaches – where the use of SPPARγMs is 
hypothesised to achieve the same therapeutic outcomes  
related to insulin sensitization, but with less adverse events 
related to body weight and dyslipideamia3,6,8.   In the 2007 
study led by Carmona8, the experimental molecule S-26948 
showed evidence of such traits, in that it exhibited a 
differential coactivator recruitment with respect to 
rosiglitazone, being unable to form neither PPARγ/DRIP205 
nor PPARγ/PGC-1α complexes. The same study showed, 
however, that S-26948 was able to dose-dependently activate 
PPARγ, with a comparable EC50  and ligand binding affinity 
(LBA) to rosiglitazone, all the while not contributing to the 
increase in triglyceride concentration, hence not inducing 
weight gain in animal diabetic models, as opposed to 
rosiglitazone.8  
In a study led by Blanc-Delmas9 in 2006, S-26948 
was described as being a chemical derivative of the TZDs, 
where both structural backbones can be divided into three 
separate regions  (Fig. 1): the acidic head (A), the linker 
region (B), and the hydrophobic tail (C). In synthesizing S-
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26948, the thiazolidine-2,4-dione moiety (Fig. 1) was 
replaced with a non-cyclic 1,3-dicarbonyl derivative - the 
dimethyl malonate moiety (Fig.1).9 The methylamino-
pyridin-2-yl moiety in rosiglitazone, was in turn, replaced 
with a benzazolonic heterocycle – benzaldehyde-2(3H)-
benzothiazolone (Fig. 1) while the linker region – 2-
ethoxybenzyl, remained the same.9  
Therefore, we have identified S-269488,9  as a 
suitable lead for this study, and as a template for novel 
structure generation. In choosing a PPARγ crystallographic 
structure, protein data bank (PDB) deposition 1FM610 was 
chosen for the purpose of this drug design exercise, since it is  
bound to rosiglitazone – to which, its derivative S-269489  
was already compared during in vivo studies8.  
Therefore, it was decided to obtain and compare the 
conformations of S-26948 which bind with highest affinity to 
the three receptor conformations, and thence use these 
posologies to generate novel molecular cohorts in a de novo  
drug design approach. 
 
              
 
 
Figure 1: A 2-Dimensional representation of the molecular similarities between rosiglitazone (above) and S -26948 
(below); showing the changes carried out during the synthesis of S -26948. A denotes the acidic head, B the linker region, 
while C the hydrophobic tail. 
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Materials and Methods: 
This study utilised a receptor based drug design 
approach12 having a similar framework to that used by 
Ciantar13 et al in 2012. The PPARγ ligand binding pocket 
(LBP) obtained from the rosiglitazone bound coordinates of 
PPARγ (PDB entry 1FM6)10 was used as a template for the 
development of novel structures – all with the potential of 
obtaining glycaemic control in vivo, without, in this case, 
predisposing the patient to cardiac irregularities and side 
effects, as did the recently withdrawn rosiglitazone7. In order 
to facilitate the computational process, PDB entry 1FM610 
was edited in a process that sought to remove all moieties co-
crystallised with the protein during X-ray crystallography that 
were not considered critical to ligand binding. Therefore, 
prior to lead docking, the PDB entry 1FM610 was modelled in 
Sybyl-X® v1.1 with the initial removal of one of its dimers, 
followed by removal of crystallised water molecules at a 
distance ≥ 5 Å from the LBP, and the extraction of its 
cognate ligand rosiglitazone from its LBP. The two dimers in 
PDB entry 1FM6 were found to be similar, with the only 
differences being those pertaining to the steroid receptor 
coactivator-1 (SRC-1) peptides, which are not involved in 
ligand binding.10 Therefore, one of the two dimers (composed 
of chains U, V, X and Y of PDB entry 1FM6)10 was 
arbitrarily chosen in this preliminary step on the premise that 
either dimer would yield identical results.  
Next, the score algorithm was used in order to 
calculate the predicted in silico LBA (pKd) of rosiglitazone 
for its cognate LBP. Sybyl-X® v1.1 was then used in order to 
construct de novo and minimise S-26948, which was  
subsequently guided, using the similarity suite algorithm of 
Sybyl-X® v1.1 into the rosiglitazone bound conformation of 
the PPARγ LBP (PDB entry 1FM6)10 with conformational 
freedom being allowed within the confines of the respective 
PPARγ LBP. This algorithm subjected S-26948 to bond 
rotation, torsion and bending into a number of alternative 
positions, or conformations, all based on the bioactive 
conformation of rosiglitazone, thereby resulting in the 
identification of the 20 highest affinity S-26948 conformers 
for the rosiglitazone bound PPARγ LBP (PDB entry 
1FM6).10 This was followed by binding energy calculations  
for each conformer, expressed in kcalmol-1 and computed 
using Sybyl-X® v1.1. The in silico  predicted LBA (pKd) of 
each conformer was obtained following scoring using X-
SCORE® v1.3,14 and a graph of LBA (pKd) and binding 
energies (kcalmol-1) (y-axis) versus conformer number (x-
axis) were plotted for the rosiglitazone bound PPARγ LBP 
(PDB entry 1FM6)10  (Fig. 2). From this conformer cohort, 
the best conformer was chosen on the basis of the highest 
LBA (pKd) and lowest binding energy – using binding 
energy and binding affinity graphs, and also using 
visualisation tools such as VMD® v1.915 in order to observe 
the conformers visually (Figs. 2 and 3).  
 
 
 
 
 
 
 
Figure 2: Graph showing the predicted in silico average ligand binding affinity (pKd) and binding energy (kcalmol -1) of 
the 20 different S-26948 conformers for the rosiglitazone bound conformation of PPARγ LBP (PDB entry 1FM6). Chosen 
conformer 17 is marked in green 
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Graph of  predicted in silico average ligand binding affinity (pKd) and binding energy 
(kcalmol-1) of the 20 conformers of S-26948 generated within the rosiglitazone bound 
conformation of the PPARγ_LBP (PDB entry 1FM6)   
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Figure 3: A 3-dimensional representation of rosiglitazone 
(white) and S -26948 conformer 17 (cyan) showing 
alternative binding modalities, rendered using VMD® 
v1.9 
 
 
Analysis of LBA, corresponding binding energy 
and of visual representations, led to the identification of one 
particular conformer (conformer 17) within the rosiglitazone 
bound conformation of the PPARγ LBP (PDB entry 1FM6)10. 
Conformer 17 was considered significant from a drug design 
perspective owing to the fact that it exhibited an alternative 
orientation with respect to rosiglitazone, when the positioning 
of the functional moieties was compared (Fig. 3). More 
specifically, the dimethyl malonate moiety, representing the 
acidic head of S-26948, was superimposed on the 
methylamino-pyridin-2-yl moiety of rosiglitazone, as 
opposed to thiazolidine-2,4-dione moiety, which is the acidic 
head of rosiglitazone (Fig. 3). Moreover, the benzaldehyde-
2(3H)-benzothiazolone moiety, representing the hydrophobic 
tail of S-26948, was superimposed on the acidic head of 
rosiglitazone, that is, the thiazolidine-2,4-dione  moiety (Fig. 
3). For this reason, it was decided to explore the possibility of 
alternative binding modalities within the PPARγ LBP, via a 
drug design exercise, aiming at the generation of novel 
molecules with high affinity to the same LBP, while also 
having an alternative binding modality with respect to known 
PPARγ agonists as is rosiglitazone.  
Sybyl-X® v1.1 was used in order to model 
conformer 17, creating seed structures retaining, as evidenced 
by structure activity relationship (SAR) studies found in the 
literature3,9, the moieties considered fundamental to partial 
agonism at the PPARγ LBP. These moieties were found to be 
the acidic head, as exemplified via the dimethyl malonate 
moiety within  S-26948, and the hydrophobic tail,  
exemplified via the benzaldehyde-2(3H)-benzothiazolone 
moiety.9 Hence, 3 seed structures were created, Seed A 
comprising the acidic head, Seed B the hydrophobic tail, and 
Seed C having both these moieties without the atoms linking 
the extremities (Fig. 4). These seeds were assigned growing 
sites, (through the designation of H.spc atoms) at which 
molecular growth was permitted, within the confines of the 
PPARγ LBP. 
The ‘pocket’ algorithm within LigBuilder ® v1.216  
was used in order to map and analyse the 3-Dimensional 
structure of the rosiglitazone bound PPARγ LBP, also taking 
into account the nature of the amino acids lining the LBP. 
However this LBP map was only capable of  accommodating 
Seed A (Fig. 4) which comprised the acidic head analogous  
to that of rosiglitazone. Seed B and consequently Seed C, 
(Fig 4) could not be rationally accommodated within the LBP 
space circumscribed by rosiglitazone when this was 
complexed with PPARγ. For this reason, a new LBP map was 
created, again using the ‘pocket’ module of LigBuilder®  
v1.216, this time based on the bound coordinates of S-26948 
conformer 17. The 3 seeds were consequently docked within 
this novel pharmacophoric space which represented the 
newly identified binding modality of S-26948 conformer 17 
at the interior of the PPARγ receptor. Following docking, the 
‘grow’ (Seeds A and B) and ‘link’ (Seed C) algorithms of 
LigBuilder® v1.216 were invoked such that unidirectional 
growth could be sustained in the case of Seeds A and B, and 
that the separate moieties of Seed C could be joined together 
by a novel linker region.  
In the analysis phase, where de novo generation 
created a large number of molecules, sample molecules were 
chosen from each family, on the notion that members of the 
same family present with similar structural moieties. The two 
molecules with the highest pKd and the two with the lowest 
pKd of each family of molecules were arbitrarily chosen, 
while an additional 2 molecules with intermediate p Kd were 
chosen where families had a larger number of molecules. 
This was possible since members of the same family had 
similar structural characteristics, and were all listed in order 
of decreasing pKd – as computed via LigBuilder® v1.2.16 The 
sample molecules were then rendered in Molsoft® ICM-
Browser in both 2-Dimension and 3-Dimension, and analysed 
according to Lipinski Rule17 compliance, the presence and 
locus of Hydrogen bond (H-bond) forming moieties, the 
sterric nature of the side chains – i.e. whether elongated 
aliphatic, or rigid and cyclic; and according to the presence or 
absence of intra-molecular H-bonding – owing to the fact that 
this could potentially hinder favourable interactions with the 
LBP. Binding energy (kcalmol-1) calculations for the sample 
molecules were then computed using Sybyl-X® v1.1 and 
binding energy – binding affinity graphs were plotted in order 
to identify the de novo molecules with the highest pKd and 
lowest binding energy (kcalmol-1)  on the basis of highest 
LBA and greatest stability respectively.  
 
Figure 4: A 2-dimensional representation of the moieties 
of S-26948 chosen to be used as seeds: the benzaldehyde-
2(3H)-benzothiazolone moiety (left) was used as Seed B; 
the dimethyl malonate moiety (right) was used as Seed A, 
while both concomitantly were used as Seed C. The green 
bonds represent the growing sites assigned. The figure 
was rendered using Symyx® Draw v 4.0.  
 
 
 
Results: 
Three Novel structures were generated from Seed 
A. These structures were not compliant with the stipulations 
of Lipinski et al,17 in predicting in vivo bioavailability – since 
all 3 had values for LogP over 5; with values ranging from 
5.11 – 5.94, and a molecular mass over 500; with values 
ranging from 576 – 590. On the other hand, de novo design 
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using Seed B gave rise to 200 novel structures all of which 
were Lipinski Rule17 compliant.  
Furthermore, de novo design using Seed C yielded 
only 3 novel molecules all of which Lipinski Rule17  
compliant. 
Therefore, a total of 206 molecules were generated 
in the de novo design phase of this study, while, of these, 203 
(98.5%) were found to be Lipinski Rule17 compliant. A total 
sample of 31 molecules were chosen for analysis. 
The pKd for the 206 de novo molecules generated 
ranged from 5.08 to 7.94, while binding energy ranged from 
112.063 kcalmol-1 to 453.377 kcalmol-1. Moreover, molecular 
weight ranged from 305 to 590, and LogP ranged from 3.01 
to 5.94. 
The highest pKd recorded of all 206 molecules, 
having a value of 7.94 – which was considerably higher than 
that recorded for the cognate ligand rosiglitazone at 6.62, 
belonged to the Seed B cohort (Figs. 5 and 6)  
 
Figure 5: A 2-dimensional and 3-dimensional representation of the de novo generated molecule with the highest pKd – 
Molecule 1 of the Seed B cohort, as rendered in Molsoft® ICM Browser 
 
When compared to the values of S-26948 conformer 17, molecules pertaining to the Seed C cohort, were seen to have a lower 
pKd, at values of 5.60, 5.50 and 5.43; and a lower binding energy, at values of 453.377 kcalmol-1, 360.756 kcalmol-1, and 
338.870 kcalmol-1 respectively.  
 
Figure 6: Graph showing the predicted in silico average ligand binding affinity (pKd) and binding energy (kcalmol -1) of 
the sample de novo generated structures chosen from the Seed B cohort of S -26948 conformer 17, as generated within the 
S-26948 conformer 17 bound conformation of PPARγ_LBP (PDB entry 1FM6). Highest pKd value (molecule 1; 7.94) with 
corresponding binding energy value (140.234 kcalmol-1) are marked in green 
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Discussion: 
Analysis of the de novo generated molecular cohort  
is indicative of which structural moieties predispose to 
increased LBA (pKd). Specifically, it was apparent that an 
aliphatic chain terminating in a cyclic moiety within the 
hydrophobic locus was favorable to binding. Moreover, 
within the linker region, a cyclic substitution presented with a 
higher pKd, while a short aliphatic side chain terminating in a 
lateral H-bond donor was also favorable to binding. At this 
same region, a H-bond acceptor close to the acidic locus was 
found to increase pKd.  Within the acidic region, a rigidified 
aliphatic side chain yielded molecules with a higher pKd, and 
was found more favorable to binding with respect to a cyclic 
moiety. Terminal H-bond forging moieties within the acidic 
region were also found to increase pKd.  
Moreover, molecules within the Seed C cohort  
were all generated having a longer linker region when 
compared to S-26948, and a bulkier moiety close to the 
hydrophobic region –  which could have caused sterric 
hindrance, leading to a lower pKd. 
In exploring an alternative binding modality of 
ligands at the PPARγ LBP, as delineated via the orientation 
of S-26948 conformer 17, we have identified a hitherto 
unexplored channel within PPARγ, which is capable of being 
stabilised through small molecule binding. This new channel  
was able to accommodate a series of novel generated 
structures – having the structural prerequisites for partial 
agonism at the PPARγ LBP, while also abiding to the 
stipulations made by Lipinski et al17 –  which are the gold 
standard predictors of in vivo bioavailability. Further 
development of these in silico designed molecules  could lead 
to a different coactivator recruitment – via an alternative H12 
stabilisation; hence potentially reducing the possibility of 
inducing cardiac side effects which caused the marketing 
authorisation withdrawal of the TZD rosiglitazone7.  
Visual analysis of the binding pockets delineated 
by rosiglitazone and S-26948 conformer 17 within the 
PPARγ LBP, confirmed that a deeper, hydrophobic pocket 
was penetrated by the acidic head of S-26948 conformer 17, 
which is thought to be a similar locus to that penetrated by 
farglitazar18. More specifically, the hydrophobic area 
penetrated by rosiglitazone via its hydrophobic tail, and 
known to bind the bulkier hydrophobic tail of farglitazar18  
was also confirmed to be penetrated by the acidic head of S-
26948 conformer 17 (Fig.7). Moreover, a theoretical novel 
binding pocket was penetrated via the benzaldehyde moiety 
of S-26948 conformer 17, since despite the superimposition 
of the latter moiety on the coordinates of the acidic 
thiazolidine-2,4-dione head of rosiglitazone, a high affinity S-
26948 conformation (pKd: 6.83) comparable to that of 
rosiglitazone (6.62) was obtained. 
 
 
Figure 7: A 3-dimensional representation of the 
rosiglitazone bound (a) and the S -26948 conformer 17 
bound (b) configuration of the PPARγ LBP. 
Superimposition of the pockets (c) and (d) reveals a 
deeper pocket penetrated via the S -26948 conformer 17 
delineated LBP. Changes are highlighted via the green 
circle, within which, in pocket (a), the hydrophobic tail of 
rosiglitazone is docked, while in pocket (b) the dimethyl 
malonate acidic head of S -26948 is docked. At the 
opposite terminal lies the theoretical novel binding 
pocket, penetrated via the benzaldehyde-2(3H)-
benzothiazolone moiety at the opposing locus (blue circle) 
 
 
 
Furthermore, the novel binding modality of S-
26948 conformer 17 was identified within the rosiglitazone 
bound PPARγ LBP (PDB entry 1FM6)10 according to a 
model that assumed a static LBP, and a small molecule that 
was allowed conformational rotation within a consequently 
confined space – which did not have the ability to move in 
tandem with the ligand. Nonetheless, it is probable, that the 
area within the PPARγ receptor currently assumed to form 
the LBP is actually larger than previously thought, and that 
the extended area to which this new molecular cohort binds, 
must be further exploited in the context of a rational drug 
design process. An in depth molecular dynamic study is 
essential in identifying the tandem motions of novel ligand 
and receptor – such that positive interactions could be 
further exploited in iterative optimizations. 
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